Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
Gespeichert in:
| Veröffentlicht in: | American journal of medical genetics. Part A 2019-06, Vol.179 (6), p.1069-1073 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1073 |
|---|---|
| container_issue | 6 |
| container_start_page | 1069 |
| container_title | American journal of medical genetics. Part A |
| container_volume | 179 |
| creator | Hughes, Derralynn A. Nicholls, Kathleen Sunder‐Plassmann, Gere Jovanovic, Ana Feldt‐Rasmussen, Ulla Schiffmann, Raphael Giugliani, Robert Jain, Vipul Viereck, Chris Castelli, Jeffrey P. Skuban, Nina Barth, Jay A. Bichet, Daniel G. |
| description | |
| doi_str_mv | 10.1002/ajmg.a.61105 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6593787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216249236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4575-da26c9345299ea02f1da4f0046434eacb26116487fbbd92b1a158753ab587a783</originalsourceid><addsrcrecordid>eNp9kUtv1DAURi1ERUthxxpZYssMfubBAikatQXUqgiGtXWT3Mx4lFdtDyVI_Hdc0o7KhtW1dI-PP-sj5BVnS86YeAe7brOEZcI500_ICddaLFQm5dPDWehj8tz7HWOS6TR5Ro4lywXjSpyQ39-gwTDRoaH-1oZqa_sNDQO9shtowQcItHFDR7H_NXVIHY4tVNhhH2jYooNxoran51C6idbWI3h8T89-jugs9hXOlyNJv2zjikparNdfi9Wa-rCvpxfkqIHW48v7eUq-n5-tVx8Xl9cXn1bF5aJSOtWLGkRS5VJpkecITDS8BtUwphIlFUJVivj7RGVpU5Z1LkoOXGepllDGAWkmT8mH2Tvuyw7rKsZ30JrR2Q7cZAaw5t9Nb7dmM_wwic5lmqVR8OZe4IabPfpgdsPe9TGzEYInQuVCJpF6O1OVG7x32Bxe4MzclWXuyjJg_pYV8dePUx3gh3YioGbg1rY4_Vdmis9XF8Xs_QNiC6Hm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216249236</pqid></control><display><type>article</type><title>Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Hughes, Derralynn A. ; Nicholls, Kathleen ; Sunder‐Plassmann, Gere ; Jovanovic, Ana ; Feldt‐Rasmussen, Ulla ; Schiffmann, Raphael ; Giugliani, Robert ; Jain, Vipul ; Viereck, Chris ; Castelli, Jeffrey P. ; Skuban, Nina ; Barth, Jay A. ; Bichet, Daniel G.</creator><creatorcontrib>Hughes, Derralynn A. ; Nicholls, Kathleen ; Sunder‐Plassmann, Gere ; Jovanovic, Ana ; Feldt‐Rasmussen, Ulla ; Schiffmann, Raphael ; Giugliani, Robert ; Jain, Vipul ; Viereck, Chris ; Castelli, Jeffrey P. ; Skuban, Nina ; Barth, Jay A. ; Bichet, Daniel G.</creatorcontrib><identifier>ISSN: 1552-4825</identifier><identifier>EISSN: 1552-4833</identifier><identifier>DOI: 10.1002/ajmg.a.61105</identifier><identifier>PMID: 30920142</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>1-Deoxynojirimycin - administration & dosage ; 1-Deoxynojirimycin - adverse effects ; 1-Deoxynojirimycin - analogs & derivatives ; 1-Deoxynojirimycin - therapeutic use ; alpha-Galactosidase - administration & dosage ; alpha-Galactosidase - therapeutic use ; Drug Substitution ; Enzyme Replacement Therapy - methods ; Fabry Disease - diagnosis ; Fabry Disease - genetics ; Fabry Disease - metabolism ; Fabry Disease - therapy ; Fabry's disease ; Female ; Humans ; Male ; Research Letter ; Research Letters</subject><ispartof>American journal of medical genetics. Part A, 2019-06, Vol.179 (6), p.1069-1073</ispartof><rights>2019 The Authors. published by Wiley Periodicals, Inc.</rights><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4575-da26c9345299ea02f1da4f0046434eacb26116487fbbd92b1a158753ab587a783</citedby><cites>FETCH-LOGICAL-c4575-da26c9345299ea02f1da4f0046434eacb26116487fbbd92b1a158753ab587a783</cites><orcidid>0000-0001-9655-3686 ; 0000-0003-4531-9173</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajmg.a.61105$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajmg.a.61105$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30920142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hughes, Derralynn A.</creatorcontrib><creatorcontrib>Nicholls, Kathleen</creatorcontrib><creatorcontrib>Sunder‐Plassmann, Gere</creatorcontrib><creatorcontrib>Jovanovic, Ana</creatorcontrib><creatorcontrib>Feldt‐Rasmussen, Ulla</creatorcontrib><creatorcontrib>Schiffmann, Raphael</creatorcontrib><creatorcontrib>Giugliani, Robert</creatorcontrib><creatorcontrib>Jain, Vipul</creatorcontrib><creatorcontrib>Viereck, Chris</creatorcontrib><creatorcontrib>Castelli, Jeffrey P.</creatorcontrib><creatorcontrib>Skuban, Nina</creatorcontrib><creatorcontrib>Barth, Jay A.</creatorcontrib><creatorcontrib>Bichet, Daniel G.</creatorcontrib><title>Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study</title><title>American journal of medical genetics. Part A</title><addtitle>Am J Med Genet A</addtitle><subject>1-Deoxynojirimycin - administration & dosage</subject><subject>1-Deoxynojirimycin - adverse effects</subject><subject>1-Deoxynojirimycin - analogs & derivatives</subject><subject>1-Deoxynojirimycin - therapeutic use</subject><subject>alpha-Galactosidase - administration & dosage</subject><subject>alpha-Galactosidase - therapeutic use</subject><subject>Drug Substitution</subject><subject>Enzyme Replacement Therapy - methods</subject><subject>Fabry Disease - diagnosis</subject><subject>Fabry Disease - genetics</subject><subject>Fabry Disease - metabolism</subject><subject>Fabry Disease - therapy</subject><subject>Fabry's disease</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Research Letter</subject><subject>Research Letters</subject><issn>1552-4825</issn><issn>1552-4833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUtv1DAURi1ERUthxxpZYssMfubBAikatQXUqgiGtXWT3Mx4lFdtDyVI_Hdc0o7KhtW1dI-PP-sj5BVnS86YeAe7brOEZcI500_ICddaLFQm5dPDWehj8tz7HWOS6TR5Ro4lywXjSpyQ39-gwTDRoaH-1oZqa_sNDQO9shtowQcItHFDR7H_NXVIHY4tVNhhH2jYooNxoran51C6idbWI3h8T89-jugs9hXOlyNJv2zjikparNdfi9Wa-rCvpxfkqIHW48v7eUq-n5-tVx8Xl9cXn1bF5aJSOtWLGkRS5VJpkecITDS8BtUwphIlFUJVivj7RGVpU5Z1LkoOXGepllDGAWkmT8mH2Tvuyw7rKsZ30JrR2Q7cZAaw5t9Nb7dmM_wwic5lmqVR8OZe4IabPfpgdsPe9TGzEYInQuVCJpF6O1OVG7x32Bxe4MzclWXuyjJg_pYV8dePUx3gh3YioGbg1rY4_Vdmis9XF8Xs_QNiC6Hm</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Hughes, Derralynn A.</creator><creator>Nicholls, Kathleen</creator><creator>Sunder‐Plassmann, Gere</creator><creator>Jovanovic, Ana</creator><creator>Feldt‐Rasmussen, Ulla</creator><creator>Schiffmann, Raphael</creator><creator>Giugliani, Robert</creator><creator>Jain, Vipul</creator><creator>Viereck, Chris</creator><creator>Castelli, Jeffrey P.</creator><creator>Skuban, Nina</creator><creator>Barth, Jay A.</creator><creator>Bichet, Daniel G.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9655-3686</orcidid><orcidid>https://orcid.org/0000-0003-4531-9173</orcidid></search><sort><creationdate>201906</creationdate><title>Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study</title><author>Hughes, Derralynn A. ; Nicholls, Kathleen ; Sunder‐Plassmann, Gere ; Jovanovic, Ana ; Feldt‐Rasmussen, Ulla ; Schiffmann, Raphael ; Giugliani, Robert ; Jain, Vipul ; Viereck, Chris ; Castelli, Jeffrey P. ; Skuban, Nina ; Barth, Jay A. ; Bichet, Daniel G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4575-da26c9345299ea02f1da4f0046434eacb26116487fbbd92b1a158753ab587a783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>1-Deoxynojirimycin - administration & dosage</topic><topic>1-Deoxynojirimycin - adverse effects</topic><topic>1-Deoxynojirimycin - analogs & derivatives</topic><topic>1-Deoxynojirimycin - therapeutic use</topic><topic>alpha-Galactosidase - administration & dosage</topic><topic>alpha-Galactosidase - therapeutic use</topic><topic>Drug Substitution</topic><topic>Enzyme Replacement Therapy - methods</topic><topic>Fabry Disease - diagnosis</topic><topic>Fabry Disease - genetics</topic><topic>Fabry Disease - metabolism</topic><topic>Fabry Disease - therapy</topic><topic>Fabry's disease</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Research Letter</topic><topic>Research Letters</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hughes, Derralynn A.</creatorcontrib><creatorcontrib>Nicholls, Kathleen</creatorcontrib><creatorcontrib>Sunder‐Plassmann, Gere</creatorcontrib><creatorcontrib>Jovanovic, Ana</creatorcontrib><creatorcontrib>Feldt‐Rasmussen, Ulla</creatorcontrib><creatorcontrib>Schiffmann, Raphael</creatorcontrib><creatorcontrib>Giugliani, Robert</creatorcontrib><creatorcontrib>Jain, Vipul</creatorcontrib><creatorcontrib>Viereck, Chris</creatorcontrib><creatorcontrib>Castelli, Jeffrey P.</creatorcontrib><creatorcontrib>Skuban, Nina</creatorcontrib><creatorcontrib>Barth, Jay A.</creatorcontrib><creatorcontrib>Bichet, Daniel G.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of medical genetics. Part A</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hughes, Derralynn A.</au><au>Nicholls, Kathleen</au><au>Sunder‐Plassmann, Gere</au><au>Jovanovic, Ana</au><au>Feldt‐Rasmussen, Ulla</au><au>Schiffmann, Raphael</au><au>Giugliani, Robert</au><au>Jain, Vipul</au><au>Viereck, Chris</au><au>Castelli, Jeffrey P.</au><au>Skuban, Nina</au><au>Barth, Jay A.</au><au>Bichet, Daniel G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study</atitle><jtitle>American journal of medical genetics. Part A</jtitle><addtitle>Am J Med Genet A</addtitle><date>2019-06</date><risdate>2019</risdate><volume>179</volume><issue>6</issue><spage>1069</spage><epage>1073</epage><pages>1069-1073</pages><issn>1552-4825</issn><eissn>1552-4833</eissn><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30920142</pmid><doi>10.1002/ajmg.a.61105</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-9655-3686</orcidid><orcidid>https://orcid.org/0000-0003-4531-9173</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-4825 |
| ispartof | American journal of medical genetics. Part A, 2019-06, Vol.179 (6), p.1069-1073 |
| issn | 1552-4825 1552-4833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6593787 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | 1-Deoxynojirimycin - administration & dosage 1-Deoxynojirimycin - adverse effects 1-Deoxynojirimycin - analogs & derivatives 1-Deoxynojirimycin - therapeutic use alpha-Galactosidase - administration & dosage alpha-Galactosidase - therapeutic use Drug Substitution Enzyme Replacement Therapy - methods Fabry Disease - diagnosis Fabry Disease - genetics Fabry Disease - metabolism Fabry Disease - therapy Fabry's disease Female Humans Male Research Letter Research Letters |
| title | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T14%3A26%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20switching%20to%20Migalastat%20from%20enzyme%20replacement%20therapy%20in%20Fabry%20disease:%20Experience%20from%20the%20Phase%203%20ATTRACT%20study&rft.jtitle=American%20journal%20of%20medical%20genetics.%20Part%20A&rft.au=Hughes,%20Derralynn%20A.&rft.date=2019-06&rft.volume=179&rft.issue=6&rft.spage=1069&rft.epage=1073&rft.pages=1069-1073&rft.issn=1552-4825&rft.eissn=1552-4833&rft_id=info:doi/10.1002/ajmg.a.61105&rft_dat=%3Cproquest_pubme%3E2216249236%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216249236&rft_id=info:pmid/30920142&rfr_iscdi=true |